| Literature DB >> 35565881 |
Georgiana-Emmanuela Gilca-Blanariu1, Anca Trifan1,2, Manuela Ciocoiu1, Iolanda Valentina Popa1, Alexandru Burlacu1,3, Gheorghe G Balan1,2, Andrei Vasile Olteanu1, Gabriela Stefanescu1,2.
Abstract
The altered magnesium status in inflammatory bowel disease (IBD) patients may have a significant clinical imprint considering its role in cell signaling and genomic stability, as well as its involvement in IBD patients' fatigue. Our study pioneers the investigation of magnesium hair concentration patterns in an adult population of IBD patients. The hair magnesium concentration in IBD patients is compared to healthy controls in order to identify correlations between the magnesium status and relevant parameters related to disease activity, psychological status, and sleep quality. We report a significantly lower hair magnesium concentration within the IBD group compared to healthy controls (95%CI: 0.006-0.062; p = 0.017) and lower levels in CD compared to UC (95%CI: -0.061--0.002; p = 0.038). We identified a borderline statistical significance between the hair magnesium concentration and UC disease activity (95%CI; -0.679-0.008; p = 0.055) and a significantly lower magnesium concentration in patients who reported increased sleep latency (95%CI -0.65--0.102; p = 0.011) or decreased sleep duration (95%CI -0.613--0.041; p = 0.028). Our results advance several hypotheses with substantial clinical impact to be confirmed in future studies. Magnesium levels appear to be modified in IBD patients, which suggests it either plays a primary role in disease pathophysiology or a is result of the disease's evolution. Magnesium could be used in predictive models for clinical/subclinical disease activity. Moreover, magnesium supplementation may improve IBD evolution and sleep quality for patients with a deficit of this mineral. However, confirmatory evidence-based studies are needed to generate specific dosing, time of supplementation, and optimum monitoring of magnesium status in IBD patients.Entities:
Keywords: HADS; PSQI; anxiety; depression; inflammatory bowel disease; insomnia; magnesium; sleep; sleep quality
Mesh:
Substances:
Year: 2022 PMID: 35565881 PMCID: PMC9102374 DOI: 10.3390/nu14091914
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Patient characteristics.
| Patient Characteristics | Study Group | Control Group | ||
|---|---|---|---|---|
| UC ( | CD ( | |||
| Age, median (Q25; Q75) | 43.5 (30; 59.5) | 32 (29; 42) | 0.05 § | |
| 46 (32.5; 65.5) | 33 (27.5; 44.5) | |||
| Sex (M/F), | 19/18 (51.4/48.6) | 16/15 (51.6/48.4) | 0.981 Ϯ | |
| 13/12 (52/48) | 6/6 (50/50) | |||
| BMI | 21.97 ± 1.5 | 23.08 ± 2.2 | 0.259 # | |
| 22.61 ± 1.95 | 21.97 ± 1.5 | |||
| Disease activity score | Mayo score 3 (1; 7) | CDAI score 146.5 (52.5; 276.5) | ||
| Active disease, | 22 (59.5%) | NA | NA | |
| 16 (64% *) | 6 (50% *) | NA | 0.65 Ϯ | |
* Percentage according to disease subtype, § Kruskal–Wallis test, Ϯ Chi-square test, # Student’s t-test. UC-ulcerative colitis, CD—Crohn’s disease, BMI—body mass index, CDAI—Crohn’s disease activity index, SD—standard deviation, NA—not applicable.
Figure 1(A) Evaluating the difference in hair magnesium concentration between IBD (inflammatory bowel disease) patients and the control group. (B) Evaluating the difference in hair magnesium concentration between CD (crohn’s disease)and UC (ulcerative colitis).
Figure 2Evaluating the difference in hair magnesium concentration for UC patients based on disease activity.
Figure 3Logistic regression model for predicting UC disease activity based on magnesium, CRP (C reactive protein), and serum albumin level.
Figure 4Evaluating the correlation between hair magnesium concentration and sleep latency (component 2 of the PSQI score) among IBD patients.
Figure 5Evaluating the correlation between hair magnesium concentration and sleep duration (component 3 of the PSQI score) among IBD patients. PSQI: Pittsburgh Sleep Quality Index.
Point–biserial correlations between magnesium hair concentration and PSQI components.
| PSQI Component | t | df |
| CI |
|---|---|---|---|---|
| Global | −1.05 | 35 | 0.3 | −0.472, 0.158 |
| Component 1—subjective sleep quality | −1.212 | 35 | 0.234 | −0.493, 0.132 |
| Component 2—sleep latency | −2.681 | 35 | 0.011 | −0.65, −0.102 |
| Component 3—Sleep duration | −2.285 | 35 | 0.028 | −0.613, −0.041 |
| Component 4—Habitual sleep efficiency | −0.706 | 35 | 0.485 | −0.426, 0.214 |
| Component 5—sleep disturbances | 0.644 | 35 | 0.524 | −0.224, 0.418 |
| Component 6—Use of sleeping medication | −0.942 | 35 | 0.353 | −0.224, 0.418 |
| Component 7—Daytime dysfunction | −0.725 | 35 | 0.474 | −0.429, 0.211 |
CI = confidence interval. PSQI: Pittsburgh Sleep Quality Index.